An ultra-scalable biomanufacturing platform for personalized regenerative medicines
Treatments using stem cells created from a patient's own cells, known as autologous induced pluripotent stem cells (iPSC), are showing great potential for treating various medical conditions. This approach, which falls under personalized regenerative medicine, could be key in not just managing but possibly curing diseases such as Parkinson's, heart disease, and age-related vision loss. However, the challenge lies in the fact that the current methods of producing these treatments are labor-intensive and handcrafted, making it difficult to produce them on a large scale to meet the demand of many patients.
What is the Solution?
Cellino is building an ultra-scalable biomanufacturing platform to manufacture iPSCs to unlock
- personalized, affordable regenerative medicine treatments for a range of diseases affecting
- hundreds of millions of patients. The company’s platform combines advanced biology, precise
- lasers, image-guided artificial intelligence, and a robust software infrastructure to manufacture
- high-quality cells autonomously.
Cellino’s bioprocess is designed to enhance batch-to-batch efficiency and patient-to-patient reliability via autonomous iPSC biomanufacturing in a closed growth chamber—without open cell transfers that risk cell damage and contamination. This enables a patient-specific, sealed “cassette” that forms the basis for highly scalable manufacturing. The background image on this page shows the design for a future version ofCellino’s modular biomanufacturing system, which will enable the processing of thousands of patient samples simultaneously.
What EQT Foundation loves about Cellino
We absolutely love Cellino’s innovative approach to biomanufacturing, particularly its ultra-scalable platform that could make personalized regenerative medicine treatments more accessible for millions of patients, and their integrated approach of combining advanced biology, precision lasers, AI-driven image guidance, and robust software to produce high-quality cells efficiently. We absolutely love this new wave of precision medicine that holds great promise of curing many of the diseases that we have limited treatments for today.
ThinQ is the must-bookmark publication for the thinking investor.
Do You Want to Know More?
Get in touch with us and take the first step to successive growth.
Get the Latest Updates
Subscribe to EQT Foundation's press releases and updates.